Literature DB >> 23111573

Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER Cohort.

Maiko Sakamoto1, Thomas D Marcotte, Anya Umlauf, Donald Franklin, Robert K Heaton, Ronald J Ellis, Scott Letendre, Terry Alexander, J A McCutchan, Erin E Morgan, Steven P Woods, Ann C Collier, Christina M Marra, David B Clifford, Benjamin B Gelman, Justin C McArthur, Susan Morgello, David Simpson, Igor Grant.   

Abstract

BACKGROUND: The HIV Dementia Scale (HDS) was developed to screen for HIV-associated neurocognitive disorders (HAND), but concerns have persisted regarding its substandard sensitivity. This study aimed to examine the classification accuracy of the HDS using raw and norm-based cut points and to evaluate the contribution of the HDS subtests to predicting HAND.
METHODS: A total of 1580 HIV-infected participants from 6 US sites completed the HDS, and a gold standard neuropsychological battery, on which 51% of participants were impaired.
RESULTS: Sensitivity and specificity to HAND using the standard raw HDS cut point were 24% and 92%, respectively. The raw HDS subtests of attention, recall, and psychomotor speed significantly contributed to classification of HAND, whereas visuomotor construction contributed the least. A modified raw cut point of 14 yielded sensitivity of 66% and specificity of 61%, with cross-validation. Using norms also significantly improved sensitivity to 69% with a concomitant reduction of specificity to 56%, whereas the positive predictive value declined from 75% to 62% and negative predictive value improved from 54% to 64%. The HDS showed similarly modest rates of sensitivity and specificity among subpopulations of individuals with minimal comorbidity and successful viral suppression.
CONCLUSIONS: Findings indicate that while the HDS is a statistically significant predictor of HAND, particularly when adjusted for demographic factors, its relatively low diagnostic classification accuracy continues to hinder its clinical utility. A raw cut point of 14 greatly improved the sensitivity of the previously established raw cut score, but may be subject to ceiling effects, particularly on repeat assessments.

Entities:  

Mesh:

Year:  2013        PMID: 23111573      PMCID: PMC3529802          DOI: 10.1097/QAI.0b013e318278ffa4

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  35 in total

1.  Stroop performance in drug users classified by HIV and hepatitis C virus serostatus.

Authors:  Eileen M Martin; Richard M Novak; Michael Fendrich; Jasmin Vassileva; Raul Gonzalez; Silvana Grbesic; Gerald Nunnally; Lisa Sworowski
Journal:  J Int Neuropsychol Soc       Date:  2004-03       Impact factor: 2.892

2.  Screening subtle HIV-related cognitive dysfunction: the clinical utility of the HIV dementia scale.

Authors:  Clifford A Smith; Wilfred G van Gorp; Elizabeth R Ryan; Stephen J Ferrando; Judith Rabkin
Journal:  J Acquir Immune Defic Syndr       Date:  2003-05-01       Impact factor: 3.731

3.  Progression of HIV-associated dementia treated with HAART.

Authors:  Ryan H Dougherty; Richard L Skolasky; Justin C McArthur
Journal:  AIDS Read       Date:  2002-02

4.  Sex differences in neuropsychological performance as an effect of human immunodeficiency virus infection: a pilot study in Zambia, Africa.

Authors:  Knut A Hestad; J Anitha Menon; Mary Silalukey-Ngoma; Donald R Franklin; Mwiya L Imasiku; Kalima Kalima; Robert K Heaton
Journal:  J Nerv Ment Dis       Date:  2012-04       Impact factor: 2.254

5.  Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.

Authors:  R Paredes; A Mocroft; O Kirk; A Lazzarin; S E Barton; J van Lunzen; T L Katzenstein; F Antunes; J D Lundgren; B Clotet
Journal:  Arch Intern Med       Date:  2000-04-24

6.  Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients.

Authors:  Frank J Palella; Joan S Chmiel; Anne C Moorman; Scott D Holmberg
Journal:  AIDS       Date:  2002-08-16       Impact factor: 4.177

7.  Cognitive and affective disorders associated to HIV infection in the HAART era: findings from the NeuroICONA study. Cognitive impairment and depression in HIV/AIDS. The NeuroICONA study.

Authors:  F Starace; L Bartoli; M S Aloisi; A Antinori; P Narciso; G Ippolito; L Ravasio; M C Moioli; D Vangi; L Gennero; O V Coronado; A Giacometti; S Nappa; M L Perulli; V Montesarchio; A La Gala; F Ricci; L Cristiano; M De Marco; C Izzo; P Pezzotti; A D'Arminio Monforte
Journal:  Acta Psychiatr Scand       Date:  2002-07       Impact factor: 6.392

8.  The 50 and 100-item short forms of the Paced Auditory Serial Addition Task (PASAT): demographically corrected norms and comparisons with the full PASAT in normal and clinical samples.

Authors:  Michael C Diehr; Mariana Cherner; Tanya J Wolfson; S Walden Miller; Igor Grant; Robert K Heaton
Journal:  J Clin Exp Neuropsychol       Date:  2003-06       Impact factor: 2.475

9.  Psychomotor slowing in hepatitis C and HIV infection.

Authors:  Hans-Jürgen von Giesen; Tobias Heintges; Naghme Abbasi-Boroudjeni; Seher Kücükköylü; Hubertus Köller; Bernhard A Haslinger; Mark Oette; Gabriele Arendt
Journal:  J Acquir Immune Defic Syndr       Date:  2004-02-01       Impact factor: 3.731

10.  Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV.

Authors:  Steven Paul Woods; Julie D Rippeth; Alan B Frol; Joel K Levy; Elizabeth Ryan; Vicki M Soukup; Charles H Hinkin; Deborah Lazzaretto; Mariana Cherner; Thomas D Marcotte; Benjamin B Gelman; Susan Morgello; Elyse J Singer; Igor Grant; Robert K Heaton
Journal:  J Clin Exp Neuropsychol       Date:  2004-09       Impact factor: 2.475

View more
  11 in total

1.  Temporal processsing demands in the HIV-1 transgenic rat: Amodal gating and implications for diagnostics.

Authors:  Kristen A McLaurin; Rosemarie M Booze; Charles F Mactutus
Journal:  Int J Dev Neurosci       Date:  2016-12-28       Impact factor: 2.457

Review 2.  An Empirical Mediation Analysis of Mechanisms Underlying HIV-1-Associated Neurocognitive Disorders.

Authors:  Kristen A McLaurin; Charles F Mactutus; Rosemarie M Booze; Amanda J Fairchild
Journal:  Brain Res       Date:  2019-09-09       Impact factor: 3.252

3.  Diagnostic and prognostic biomarkers for HAND.

Authors:  Kristen A McLaurin; Rosemarie M Booze; Charles F Mactutus
Journal:  J Neurovirol       Date:  2019-01-03       Impact factor: 2.643

4.  CSF viral escape in a patient with HIV-associated neurocognitive disorder.

Authors:  Michael N Khoury; C Sabrina Tan; Marcia Peaslee; Igor J Koralnik
Journal:  J Neurovirol       Date:  2013-06-05       Impact factor: 2.643

Review 5.  Interactions between ageing and NeuroAIDS.

Authors:  Joanna Hellmuth; Benedetta Milanini; Victor Valcour
Journal:  Curr Opin HIV AIDS       Date:  2014-11       Impact factor: 4.283

6.  Neurocognitive impairment in HIV-1 clade C- versus B-infected individuals in Southern Brazil.

Authors:  Sergio Monteiro de Almeida; Clea Elisa Ribeiro; Ana Paula de Pereira; Jayraan Badiee; Mariana Cherner; Davey Smith; Ingrid Maich; Sonia Mara Raboni; Indianara Rotta; Francisco Jaime Barbosa; Robert K Heaton; Anya Umlauf; Ronald J Ellis
Journal:  J Neurovirol       Date:  2013-11-26       Impact factor: 2.643

Review 7.  A systematic review of the screening accuracy of the HIV Dementia Scale and International HIV Dementia Scale.

Authors:  Lewis John Haddow; Sian Floyd; Andrew Copas; Richard John Cary Gilson
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

8.  Increases in CSF dopamine in HIV patients are due to the dopamine transporter 10/10-repeat allele which is more frequent in HIV-infected individuals.

Authors:  Anne Horn; Carsten Scheller; Stefan du Plessis; Gabriele Arendt; Thorsten Nolting; John Joska; Sieghart Sopper; Matthias Maschke; Mark Obermann; Ingo W Husstedt; Johannes Hain; Tongai Maponga; Peter Riederer; Eleni Koutsilieri
Journal:  J Neural Transm (Vienna)       Date:  2013-09-06       Impact factor: 3.575

Review 9.  Validity of cognitive screens for HIV-associated neurocognitive disorder: a systematic review and an informed screen selection guide.

Authors:  Jody Kamminga; Lucette A Cysique; Grace Lu; Jennifer Batchelor; Bruce J Brew
Journal:  Curr HIV/AIDS Rep       Date:  2013-12       Impact factor: 5.071

10.  Reduced neural specificity in middle-aged HIV+ women in the absence of behavioral deficits.

Authors:  Chenglong Liu; Cuiwei Wang; Matthew Leclair; Mary Young; Xiong Jiang
Journal:  Neuroimage Clin       Date:  2014-12-13       Impact factor: 4.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.